CV
Univ. Prof. Dr. med. Martin L. Sos
Academic education
2000 - 2007: Medical School, University of Cologne
Scientific degrees
12/2007: MD (summa cum laude), Medical Faculty, University of Cologne, Supervisor Prof. Dr. Jürgen Wolf
06/2007: Graduation from Medical School, University of Cologne
Scientific career
2015 - present: Professor for Molecular Pathology, Institute of Pathology & Department of Translational Genomics, University of Cologne
2014 - 2015: Junior Group Leader, Department of Translational Genomics, University of Cologne
2012 - 2014: Postdoctoral Fellow, Shokat Lab, Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, USA
2010 - 2012: Clinical Research fellow at the Center of Integrated Oncology, Lung Cancer Group Cologne, University of Cologne
2007 - 2010: Postdoctoral Fellow, Thomas Lab, Max-Planck Institute for Neurological Research, Cologne
Honors/ Awards/ Memberships
2016 - 2019: present Speaker of NRW-funded research consortium within the EFRE call (EMODI)
2014 - 2018: Speaker of BMBF-funded research consortium within the e:Med call (MILES)2012 - 2014 Young Investigator Award, Prostate Cancer Foundation (PCF) USA
2013: Scholar-in-Training Award, AACR - Aflac
2011 - 2013: Young Investigator Award, International Association for the Study of Lung Cancer (IASLC)
2010 - 2011: Scholar-in-Training Award, AACR - Pezcoller Foundation
2009: Scholar-in-Training Award, American Association for Cancer Research (AACR)
2008: Award for outstanding medical thesis, German Association of Hematology and Oncology (DGHO)
2007 - 2008: Young Investigator Fellowship, Max-Planck Institute for Neurological Research, Cologne, Germany
2005 - 2007: Köln Fortune Fellowship, University of Cologne, Germany
10 most relevant publications
- Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Büttner R, Sen T, Byers LA, Reinhardt HC, Letai A, Oliver TG, Sos ML. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nat Commun. 2019; 10(1):3485.
- Fassunke J, Müller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Heimsoeth A, Dahmen I, Fischer RN, Scheffler M, Ihle MA, Priesner V, Scheel AH, Wagener S, Kron A, Frank K, Garbert K, Persigehl T, Püsken M, Haneder S, Schaaf B, Rodermann E, Engel-Riedel W, Felip E, Smit EF, Merkelbach-Bruse S, Reinhardt HC, Kast SM, Wolf J, Rauh D, Büttner R, Sos ML. Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nat Commun. 2018; 9(1):4655.
- Plenker D, Bertrand M, de Langen AJ, Riedel R, Lorenz C, Scheel AH, Müller J, Brägelmann J, Daßler-Plenker J, Kobe C, Persigehl T, Kluge A, Wurdinger T, Schellen P, Hartmann G, Zacherle T, Menon R, Thunnissen E, Büttner R, Griesinger F, Wolf J, Heukamp L, Sos ML*, Heuckmann JM* (*co-corresponding authors). Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients. Clin Cancer Res. 2018; 24(6):1337-1343.
- Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, Varga Z, Balke-Want H, French CA, Peifer M, Reinhardt HC, Örfi L, Kéri G, Ansén S, Heukamp LC, Büttner R, Rauh D, Klebl BM, Thomas RK, Sos ML. Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in NUT midline carcinoma. Cell Reports. 2017; 20(12):2833-2845.
- Plenker D, Riedel M, Brägelmann J, Dammert MA, Chauhan R, Knowles PP, Lorenz C, Keul M, Bührmann M, Pagel O, Tischler V, Scheel AH, Schütte D, Song Y, Stark J, Mrugalla F, Alber Y, Richters A, Engel J, Leenders F, Heuckmann JM, Wolf J, Diebold J, Pall G, Peifer M, Aerts M, Gevaert K, Zahedi RP, Buettner R, Shokat KM, McDonald NQ, Kast SM, Gautschi O, Thomas RK, Sos ML. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Sci Transl Med. 2017; 14; 9(394).
- Mollaoglu G, Guthrie MR, Böhm S, Brägelmann J, Can I, Ballieu PM, Marx A, George J, Heinen C, Chalishazar MD, Cheng H, Ireland AS, Denning KE, Mukhopadhyay A, Mosbruger TL, Wang J, Kohan JL, Salama M, Witt BL, Peifer M, Thomas RK, Johnson JE, Gazdar AF, Wechsler-Reya RJ, Sos ML*, Oliver TG* (*=co-corresponding authors). MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition. Cancer Cell 2017; 31:1-16.
- Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, AnsénS, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin Cancer Res 2016; 22(19):4837-47.
- Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013; 503(7477):548-51.
- Sos ML, Dietlein F, Peifer M, Schöttle J, Balke-Want H, Müller C, Koker M, Richters A, Heynck S, Malchers F, Heuckmann JM, Seidel D, Eyers PA, Ullrich RT, Antonchick AP, Vintonyak VV, Schneider PM, Ninomiya T, Waldmann H, Büttner R, Rauh D, Heukamp LC, and Thomas RK. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA 2012; 109(42):17034-9.
- Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sänger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, and Thomas RK. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44(10):1104-10.
Patents
- P2126 PCT S3: A method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to dasatinib
- US Patent 13/371,399: A method of treating lung cancer
- US provisional Patent No. 61/530,847 and 61/606,296: Novel Chemotherapeutics
Contact Information
Univ. Prof. Dr. med. Martin L. Sos
Professor (W2)
University Hospital of Cologne, University of Cologne
Molecular Pathology, Institute for Pathology
Department of Translational Genomics
